The effect of scopolamine on mental performance during microgravity simulation <b>[Abstract in English]</b>
Abstract
Objective: The optimization of mental performance and the minimization of errors can save lives and reduce the costs of a space mission. Cognition was evaluated by means of a psychological test, the Manikin Test, under the effect of scopolamine, a drug widely used to prevent or minimize the symptomatology of Space Motion Sickness, during microgravity simulation.Methods: 6º HDT (head-down tilt) was used to simulate some of the effects of microgravity. A double-blind and randomized study evaluated the effect of 0.45 mg of Scopolamine on mental performance during microgravity simulation (n = 15).
Results: Scopolamine failed to decrease mental performance during microgravity simulation when measured by means of a psychological test.
Conclusion: Further studies are needed to better clarify the interaction between Scopolamine and HDT, which will allow the development of a more effective way to prevent or to minimize the symptomatology related to space motion sickness.
KEY WORDS: MENTAL PERFORMANCE, SCOPOLAMINE, MICROGRAVITY, 6º HEAD-DOWN TILT, SPACE MOTION SICKNESS.
Downloads
Download data is not yet available.
Downloads
Published
2006-10-17
How to Cite
Russomano, T., Santos, M. A. dos, Andrade, L., Alles, M. C., Martinelli, L. K., Triches, P. F., & Azevedo, D. F. G. de. (2006). The effect of scopolamine on mental performance during microgravity simulation <b>[Abstract in English]</b>. Scientia Medica, 15(2). Retrieved from https://revistaseletronicas.pucrs.br/index.php/scientiamedica/article/view/1551
Issue
Section
Original Articles
License
Copyright
The submission of originals to Scientia Medica implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Scientia Medica as the site of original publication.
Creative Commons License
Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.
